Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.67 |
| ▸ | CA2 | P00918 | 4/20 | 0.67 |
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 1/20 | 0.67 |
| ▸ | PPARA | Q07869 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8679104 | 1.00 | CA1 (0.67) | CA1CA2CA12CA14CA7 | |
| SCHEMBL694651 | 0.92 | PPARA (0.60) | CA1CA2CA12CA14CA7 | |
| SCHEMBL1703654 | 0.90 | PPARA (0.64) | CA1CA2CA12CA14CA7 | |
| SCHEMBL7691833 | 0.90 | PPARA (0.64) | CA1CA2CA12CA14CA7 | |
| Sulfuric Acid SCHEMBL28705504 | 0.87 | CA2 (0.57) | CA1CA2CA12CA14CA7 | |
| SCHEMBL16477921 | 0.86 | CA1 (0.64) | CA1CA2CA12CA14CA7 | |
| SCHEMBL5689484 | 0.84 | CA1 (0.61) | CA1CA2CA12CA14CA7 | |
| SCHEMBL608990 | 0.84 | CA1 (0.61) | CA1CA2CA12CA14CA7 | |
| SCHEMBL805368 | 0.82 | — | — | |
| SCHEMBL1692883 | 0.82 | CA2 (0.58) | CA1CA2CA12CA14CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| WO-2023107669-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022204288-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022120353-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-2694505-B1 | HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2022-04-27 | — | — | EP | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-1389216-B1 | AVERMECTINS SUBSTITUTED IN THE 4\"-POSITION HAVING PESTICIDAL PROPERTIES | MERIAL INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20160264577-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-09-15 | — | — | US | disclosed |
| US-9346808-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-24 | — | — | US | disclosed |
| EP-0860440-A1 | Sulfonamido substituted chromane derivatives with potassium channel blocking activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-08-26 | — | — | EP | disclosed |
| WO-1998027077-A1 | 2,1,3-BENZOTHIA(OXA)DIAZOLE DERIVATIVES AND THEIR USE AS ENDOTHELIN-RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 1998-06-25 | — | — | WO | disclosed |
| WO-1997030982-A1 | 2,1,3-BENZOTHIA(OXA)DIAZOLE DERIVATIVES HAVING AN ENDOTHELIN RECEPTOR ANTAGONISTIC EFFECT | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1997-08-28 | — | — | WO | disclosed |
| EP-0791572-A1 | SUBSTITUTED BICYCLOHEPTANEDIONE DERIVATIVE AND HERBICIDE | NIPPON SODA CO., LTD. (JP) | 1997-08-27 | — | — | EP | disclosed |
| WO-1997019077-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1997-05-29 | — | — | WO | disclosed |
| US-5545838-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1996-08-13 | — | — | US | disclosed |
| US-5098924-A | Hypotensive agents and angiotensin II inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1992-03-24 | — | — | US | disclosed |
| EP-0452587-A1 | Dihydroxy sulfonamide and sulfinamide renin inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1991-10-23 | — | — | EP | disclosed |
| US-4360448-A | ORGANONITROGEN ION EXCHANGE COMPOUND | EXXON RESEARCH AND ENGINEERING CO. (US) | 1982-11-23 | — | — | US | disclosed |
| US-4136164-A | FOR USE IN FOODS, TOPICAL PREPARATIONS, AND TOBACCO | WILKINSON SWORD LIMITED (GB) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | ASNS, GLUL, GNMT | CA1 1784/4885CA2 3321/4885CA12 2289/4885 |
| US-20160264577-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | CA1 1994/4885CA2 1812/4885CA12 2719/4885 |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | CA1 4771/4885CA2 4841/4885CA12 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.